GlassScriptPhysician profile
Ross A Jensen
NPI 1568758183
$4,819.79
in general payments reported to CMS, 2019-2025
22 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $389 · 2021: $863 · 2022: $712 · 2023: $777 · 2024: $542 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,264 · Education: $99.99 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.85 |
| Education | $99.99 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $630.25 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $592.93 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $414.68 | 2019-2023 | |
| Horizon Therapeutics Plc | $348.64 | 2021-2023 | Tepezza |
| Allergan, INC. | $339.52 | 2020-2022 | |
| Alcon Vision LLC | $305.95 | 2021-2025 | Tryptyr, Argos, Hydrus Microstent |
| Abbvie INC. | $271.95 | 2022-2025 | |
| Dompe US, INC. | $262.20 | 2021-2025 | Oxervate |
| Astellas Pharma US INC | $244.76 | 2023-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $228.40 | 2024-2025 | Acthar |
| Oyster Point Pharma, INC. | $215.07 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $176.98 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $165.24 | 2021-2022 | |
| Rxsight INC | $158.19 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Coopervision INC. | $145.95 | 2019-2024 | Myday Contact Lens |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $92.04 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $59.47 | 2019 | |
| Amgen INC. | $49.04 | 2024 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $40.65 | 2023 | Eylea |
| Apellis Pharmaceuticals, INC. | $36.42 | 2023-2024 | Syfovre |
| Glaukos Corporation | $24.45 | 2024 | Ce-Marked Kxla System |
| Aerie Pharmaceuticals, INC. | $17.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.